Trial Profile
A retrospective,multicenter study assessing rate of ischemic events in patients with Atrial fibrillation treated with oral anticoagulants
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jan 2017
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Vitamin K antagonists
- Indications Ischaemia; Stroke
- Focus Therapeutic Use
- 19 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology